+0  (0%)
Previous Close 3.93
Open 3.94
Price To book 2.91
Market Cap 21.56M
Shares 5,472,000
Volume 358,175
Short Ratio 1.22
Av. Daily Volume 595,673

SEC filingsSee all SEC filings

  1. PRE 14A - Other preliminary proxy statements 17767164
  2. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17716131
  3. 8-K - Current report 17632961
  4. 8-K - Current report 17533724
  5. 8-K - Current report 162057000

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial complete.
Radiation Enteritis
Phase 3 data due 2H 2017.
SGX301 (synthetic hypericin)
Cutaneous T-Cell Lymphoma (CTCL) cancer
Seek to obtain FDA agreement on Phase 2b/3 protocol in 1H 2017
SGX942 (dusquetide)
Oral Mucositis in Patients with Head & Neck Cancer
Phase 3 initiation due 1H 2017 with data due 2H 2018 - pending funding.
Pediatric Crohn’s Disease

Latest News

  1. Today's Research Reports on Biotech Stocks to Watch: Soligenix and MannKind
  2. Efficacy Results from Soligenix's Ricin Toxin Vaccine Program to be Presented at the 20th Annual Conference on Vaccine Research
  3. Soligenix to Present at the World Orphan Drug Congress
  4. Statistically Significant Data from Late Stage Clinical Assets & Continued Funding from the Government Positions Soligenix Attractively for a Potential Suitor
  5. Soligenix, Inc. :SNGX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 29, 2017
  6. Soligenix Announces Recent Accomplishments And Year-End 2016 Financial Results
  7. Soligenix to Present Data on Dusquetide in Combating Antibiotic-Resistant Infections at the 19th Annual Superbugs & Superdrugs Conference
  8. Soligenix (SNGX): A Key Player in the Biodefense Space
  9. Soligenix to Present Results from its Ricin Toxin Vaccine Program at the Society of Toxicology 56th Annual Meeting
  10. SNGX: Potential Expansion of Synthetic Hypericin into Psoriasis
  11. Soligenix Receives European Patent for Formulation of Synthetic Hypericin to Treat Psoriasis
  12. Soligenix Announces SGX301 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency
  13. Soligenix to Present at 9th Annual Biotech Showcase Conference
  14. Soligenix (SNGX): SGX942 (Dusquetide) Could be A Game Changer for the Treatment of Oral Mucositis
  15. Soligenix Receives Positive Scientific Advice from the European Medicines Agency for SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer Patients
  16. Soligenix Announces Extension of Development Agreement with Emergent BioSolutions
  17. Soligenix Advances Collaboration with IDT Biologika
  18. Soligenix Announces Closing of Public Offering
  19. Soligenix (SNGX) Prices $5.3 million Public Offering and Completes Listing on Nasdaq
  20. Soligenix, Inc. Prices $5,277,000 Public Offering and Completes Listing on Nasdaq